Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
Apollo continues to invest in genomics technology and research for better patient care
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Subscribe To Our Newsletter & Stay Updated
